Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the three and nine months ended September 30, 2013. The Company reported net product sales of Soliris® (eculizumab) of $400.4 million in the third quarter of 2013, an increase of 36 percent from the same period in 2012.
Help employers find you! Check out all the jobs and post your resume.
